Short Interest Coverage: Could ACTELION LTD (ALIOF) Go Down?

November 29, 2016 - By Vivian Park

Short Interest Coverage: Could ACTELION LTD (ALIOF) Go Down?

The stock price of ACTELION LTD (OTCMKTS:ALIOF) recorded $7.33 in recent trading, touching $191.34 and getting interest from avid investors. It’s the latest price, but let’s analyze how the stock has been doing recently. In the past year, ACTELION LTD’s stock was 16.00%. According to the short interest report published recently, (ALIOF) had 124,700 shorted shares for 178.1 days to cover. The prior short interest was 91,200 for a $36.73 change. The 52-Week High and Low are noted here. -6.25% (High), 53.22%, (Low). The stock had 700 average volume.

Will Stock Price of ACTELION LTD (OTCMKTS:ALIOF) Getaway to Their Potential? Register to Our Newsletter Now!

When moving into land of penny stock trading, one must determine whether the risk-reward ratio is favorable. Penny stocks can be tremendously attractive. Hollywood often shows selling or trading stocks being easy and fun, with millions of dollars earned as profits. It’s important to identify that there is considerable risk involved when putting money in penny stocks. The risks list include market volatility, getting stuck with fake shell firms created for the only objective of the ‘pump and dump’. For those who are not aware with the term, pump and dump happens where brokers promote the equity until prices rise, then sell the stock, leaving novice investors to bear the loss.

Receive Latest Alerts on Stocks That Are Set to Make a Run by Registering in the Bar Below.

It is a common thing to get caught up in the excitement of penny stock email bulletins. Though the circulars are a helpful means to get ideas, wise investors still perform due diligence on interested stocks. Some penny stock circulars show a disclaimer at the bottom that states something like ‘We are not market advisors, we’ve got compensation and we may have this stock in our portfolio.’ Further study must be carried out to find out if a firm actually has businesses or is simply a home office.

Many a times, when a promotional plan is designed, there are big shareholders offloading shares they might have bought long ago, waiting for an opportunity to recoup their investments. It never indicates that these firms termed as ‘fake’ aren’t good options for short-term trading. If you have disposable money that you can put in use to make a quick trade, what a firm does is less significant than recording a win on a trade. In such a scenario, things like stock promotions are advantageous for shareholders as they throw more light on a dark or defunct firm.

Look at a promotion last year of Cynk Technology (CYNK), which surged all the way to $21.95 from low of 6 cents. The firm itself had very little to deliver as far as fundamentals or operations are concerned, and its shares price was purely led by trading activity.

Disclaimer: The information contained on this website and from any communication related to this website is for information purposes only. The material on this website does not constitute advice and you should not rely on any material in this website to make (or refrain from making) any decision or take (or refrain from making) any action.

More notable recent Actelion Ltd (OTCMKTS:ALIOF) news were published by: Reuters.com which released: “BRIEF-Meyer Burger names Braendle new CEO” on March 24, 2011, also Reuters.com with their article: “J&J makes takeover approach for Swiss drugmaker Actelion: Bloomberg” published on November 24, 2016, Bloomberg.com published: “J&J’s Actelion Comedown” on November 29, 2016. More interesting news about Actelion Ltd (OTCMKTS:ALIOF) were released by: Seekingalpha.com and their article: “Complicated chemistry! Actelion and J&J” published on November 29, 2016 as well as Bloomberg.com‘s news article titled: “Actelion Using Combination Strategy to Attack Multiple Sclerosis” with publication date: October 20, 2016.

Actelion Ltd is a Switzerland-based biopharmaceutical firm that focuses on the discovery, development and commercialization of drugs for diseases with unmet medical needs. The company has a market cap of $19.24 billion. The Firm specializes in the field of pulmonary arterial hypertension , a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs. It currently has negative earnings. The Company’s portfolio of PAH treatments includes Opsumit (macitentan), Tracleer (bosentan), Uptravi (selexipag), Veletri (epoprostenol for injection) and Ventavis (iloprost).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>